10 , e2302607 (2023)
Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who: Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 12+ lb/week Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation Carry known markers of systemic inflammation elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden
Most cases were mild and didn't lead to participants stopping treatment
Lack of oral GSH supplementation effects upon growth or changes in serum or fecal inflammatory markers in children with cystic fibrosis with pancreatic insufficiency (125) could be probably explained by the inability of the cells to uptake extracellular GSH to be used inside the cells
et al., Altern Ther Health Med (2024) Pilot study on BPC-157 for interstitial cystitis (private clinic) Orthopaedic & Wellness (2023) Peptide Dangers blog highlighting conflicts of interest and unknown risks USADA Spirit of Sport blog (2020): Warning to athletes about BPC-157s unapproved status usada.org
Trials 17 (1), 112
